New Jersey, USA-headquartered drug major Schering-Plough has announced changes to its manufacturing operations in Puerto Rico and the USA that will streamline its global supply chain and further enhance its long-term competitiveness. The company said that it is phasing out manufacturing operations at its Manati, Puerto Rico site, with the expected discontinuation of substantially all operations by the end of 2006. In addition, there will be workforce reductions at manufacturing facilities in Las Piedras in Puerto Rico and in New Jersey.
"The actions we are announcing...are another step in our Action Agenda to transform this company into a high-performance competitor for the long term," stated Fred Hassan, chief executive. "Undertaking these workforce reductions was a difficult decision. To support employees who are affected by these actions, we will be implementing a variety of programs as well as working closely with local authorities and communities to mitigate the impacts," he added.
Overall, the actions taken will result in the elimination of about 1,100 positions, primarily in 2006. Around 600 regular full-time positions will be cut in Puerto Rico, including some 550 in Manati and 50 in Las Piedras. S-P expects to continue to employ about 475 people in Las Piedras. Some 500 regular full-time positions will go in New Jersey between the Kenilworth and Union sites.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze